Dynamic contrast-enhanced MRI and diffusion kurtosis imaging for the differentiation of salivary gland tumours
Dentomaxillofacial Radiology · 2026
DOI: 10.1093/dmfr/twaf078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dentomaxillofacial Radiology, 2026. Verfasst von Jinru Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radiological Medical College, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, 250117, China. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Contrast Media, Magnetic Resonance Imaging, Diffusion Magnetic Resonance Imaging. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Jining Key Research and Development Program.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the diagnostic ability of relative values of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion kurtosis imaging (DKI) quantitative parameters for salivary gland tumours (SGTs).
Methods
A total of 107 patients with histopathologically confirmed SGTs (18 malignant [MTs], 38 pleomorphic adenomas [PAs], 31 Warthin tumours [WTs], 20 basal cell adenomas [BCAs]) underwent MRI with DKI and DCE-MRI sequences. Quantitative parameters included DCE-MRI-derived volume transfer constant (Ktrans), rate constant (Kep), fractional volume of the extravascular-extracellular space (Ve), plasma fraction (Vp), and DKI-derived mean kurtosis (MK) and mean diffusion (MD).The receiver operating characteristic (ROC) curve were used for statistical analysis. Statistical significance was set at P < 0.05.
Results
PAs exhibited the lowest MK (0.49 ± 0.15) among all groups (P < 0.05). Compared to WTs, PAs showed lower Kep (366.89 [260.06, 568.32]×10−³ min−1), higher MD (2.02 ± 0.42 × 10−³ mm2/s), and higher Ve (551.83 [388.10, 883.19]×10−³). PAs also displayed higher Ve, lower Kep, and lower Vp (85.42 [20.53, 332.72])×10−³) than BCAs, and lower Vp with higher Ve than MTs (all P < 0.05). WTs had significantly lower Ve (218.86 [142.07, 341.76]×10−³) than MTs (P = 0.001). BCAs demonstrated lower MK (0.61 ± 0.23) and higher MD (1.97 ± 0.44 × 10−³ mm2/s) compared to WTs and MTs (P < 0.05), alongside lower Ktrans (355.25 [211.88, 506.92]×10−³ min−1) and Ve (380.89 [271.28, 589.53]×10−³) than WTs (P < 0.05). Logistic regression analysis revealed enhanced discrimination: MK+Ve (AUC = 0.895) and MK + MD + Ve + Kep (AUC = 0.936) differentiated PAs from WTs; Kep + Vp + Ve distinguished PAs from BCAs (AUC = 0.843); MD + MK + Vp separated PAs from MTs (AUC = 0.854); Ktrans + MK differentiated WTs from BCAs (AUC = 0.856).
Conclusions
DKI and DCE-MRI parameters complement each other, enabling accurate SGT subtype differentiation. Combined use of these parameters achieves high diagnostic accuracy, and a stepwise diagnostic flowchart was designed to facilitate systematic discrimination among the four tumour types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiological Medical College, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, 250117, China.
- Department of Radiology, Jining No. 1 People's Hospital Affiliated to Shandong First Medical University, Jining, Shandong 272000, China.
ORCID-Profile: Ning Zheng
Förderung
- Jining Key Research and Development Program
Zitieren
APA
Yu, J., Yang, H., Zheng, N., & Shao, S. (2026). Dynamic contrast-enhanced MRI and diffusion kurtosis imaging for the differentiation of salivary gland tumours. Dentomaxillofacial Radiology. https://doi.org/10.1093/dmfr/twaf078
Vancouver
Yu J, Yang H, Zheng N, Shao S. Dynamic contrast-enhanced MRI and diffusion kurtosis imaging for the differentiation of salivary gland tumours. Dentomaxillofacial Radiology. 2026. doi:10.1093/dmfr/twaf078
BibTeX
@article{Yu2026,
author = {Yu, Jinru and Yang, Huan and Zheng, Ning and Shao, Shuo},
title = {Dynamic contrast-enhanced MRI and diffusion kurtosis imaging for the differentiation of salivary gland tumours},
journal = {Dentomaxillofacial Radiology},
year = {2026},
doi = {10.1093/dmfr/twaf078}
}
EUVIMED